Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
PARSIPPANY, N.J., March 13, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in Miami.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
